BC
AXSM icon

Bridgefront Capital’s Axsome Therapeutics AXSM Stock Holding History

Bridgefront Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$294K Sell
1,200
-424
-26% -$92K 0.08% 384
2026
Q1 		$274K Buy
+1,624
New +$281K 0.07% 412
2025
Q1 		– Sell
-10,555
Closed -$893K – 624
2024
Q4 		$893K Buy
+10,555
New +$971K 0.3% 79
2021
Q2 		– Sell
-9,257
Closed -$524K – 605
2021
Q1 		$524K Buy
+9,257
New +$651K 0.16% 215

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bridgefront Capital's AXSM Position: Q2 2026 in Review

Bridgefront Capital reduced its Axsome Therapeutics (AXSM) stake by 26% in Q2 2026, selling an estimated $92K and leaving 1,200 shares worth $294K. The position accounts for 0.08% of the portfolio, ranked #384.

Bridgefront Capital first reported a position in AXSM in Q1 2021 and has held it in 4 quarters since. The position peaked at $893K in Q4 2024. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Bridgefront Capital held 1,200 shares of Axsome Therapeutics worth $294K as of Q2 2026.
  • Bridgefront Capital sold 424 Axsome Therapeutics shares in Q2 2026, an estimated $92K.
  • Axsome Therapeutics made up 0.08% of Bridgefront Capital's portfolio in Q2 2026, its #384 holding.
  • Bridgefront Capital first reported a position in Axsome Therapeutics in Q1 2021 and has held it in 4 quarters since.
  • Bridgefront Capital's Axsome Therapeutics position peaked at $893K in Q4 2024.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.